CALASTONE
1.12.2021 09:02:08 CET | Business Wire | Press release
Calastone, the largest global funds network, has signed a partnership agreement with Microsoft, which will see the firms collaborate on the use of cloud and distributed ledger technology to create market efficiency across the global investment funds industry. By combining Calastone’s network, technology and market experience, with Microsoft’s expertise and track record in delivering capital markets solutions in Microsoft Azure, the companies will drive new opportunities for collective investments worldwide.
Calastone is leveraging its network as the foundation on which to enable the asset management industry to realise its digital transformation agenda. As investor requirements grow for accessible, low cost and innovative ways of investing, Calastone is applying the very latest technologies to build the next generation infrastructure for the distribution of investment funds.
Calastone introduced DMI Fund Services, a suite of solutions that provides fund managers, administrators and distributors a fully digital operating model, enabled through the use of cloud and DLT. In the development of DMI Fund Services, Calastone chose Azure for its reliability, security, scalability and leading-edge confidential computing platform which includes the confidential consortium framework (CCF).
CCF is an open-source framework for building a new category of secure, highly available, and performant applications that focus on multi-party confidential compute and storage. Through Calastone’s practical experience having operated DLT since 2019, the firm has selected CCF as the best framework to provide the rapid scalability and security required to operate on a global scale. This will allow for transformative fund trading and dynamic data sharing across the entire industry, in one common infrastructure.
As DMI Fund Services and Azure confidential computing evolve, the partnership between Calastone and Microsoft will deliver new capabilities, which will enable transfer agents, fund managers and fund distributors to transform how they operate and service their clients, and ultimately gain from the wholescale market efficiency to lower the overall cost of investing.
Adam Belding, Chief Technology Officer at Calastone, said, “The funds industry is at a turning point, with the need to innovate and digitally transform becoming the key goal of asset managers and asset servicers. We absolutely believe that this technology is the future for the funds industry, and for financial services generally. We have great ambitions for DMI Fund Services and our wider product set, and so we looked to Microsoft, one of the world’s leading technology companies, with a proven expertise in enabling distributed ledger and cloud solutions for the financial services sector, to help us drive towards these goals.
“Microsoft’s technologies and industry track record will enable the rapid scaling we see for DMI Fund Services, and our global funds network generally. We are excited to share this vision with Microsoft and look forward to collaborating to revolutionize the funds sector and provide a more efficient and friction-free experience for all.”
Bill Borden, Corporate Vice President of Worldwide Financial Services at Microsoft, said, “We’re excited to work with Calastone to enable innovation in the asset management and capital markets industries. Calastone’s DMI Fund Services, combined with Microsoft Azure and distributed ledger technology, unlocks a secure and scalable way for firms to access the critical data and insights they need to further enhance the client experience, significantly reduce operating costs, and develop new investment models.”
About Calastone
Calastone is the largest global funds network, connecting the world’s leading financial organisations.
Our mission is to help the funds industry transform by creating innovative new ways to automate and digitalise the global investment funds marketplace, reducing frictional costs and lowering operational risk to the benefit of all. Through this, we generate the opportunity for the industry to deliver greater value back to the end investor.
Over 2,800 clients in 51 countries and territories benefit from Calastone’s services, processing £200 billion of investment value each month.
Calastone is headquartered in London and has offices in Luxembourg, Hong Kong, Taipei, Singapore, New York, Milan and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
